Korea Pharma

032300 · KOSDAQ · ₩032300 · 한국파마

₩8,170 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩5,589

vs the current price (₩8,170)

Enterprise value
₩61B
Equity value
₩61B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩2,555
−68.7%
Base
₩5,589
−31.6%
Bull
₩11,020
+34.9%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (5.8%).

Revenue growth

  • 2.6%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

  • 2.7%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

  • 2.8%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

  • 2.9%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

Business

  • 5.8%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 2.6%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 3.1%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 26.3%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.24, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩94B
Net debt (borrowings and leases − cash and deposits)
₩373M
+ Stakes and investments
₩204M
Associates, long-term financial assets and deposits (book value)
Shares
10,906,701
Share price
₩8,170
Market cap
₩89B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩83B₩81B₩88B₩96B₩99B₩102B₩105B₩108B
Growth2.7%−2.4%7.8%2.6%2.7%2.8%2.9%3.0%
EBIT₩6.3B₩6.1B−₩887M₩5.6B₩5.7B₩5.9B₩6.1B₩6.3B
EBIT margin7.5%7.5%−1.0%5.8%5.8%5.8%5.8%5.8%
After-tax EBIT₩4.5B₩4.4B−₩643M₩4.1B₩4.2B₩4.3B₩4.4B₩4.5B
+ Depreciation₩2.2B₩2.1B₩2.3B₩2.5B₩2.6B₩2.6B₩2.7B₩2.8B
− Capital spending₩2.7B₩3.8B₩1.3B₩3B₩3.1B₩3.2B₩3.2B₩3.3B
− Working capital₩8.9B−₩9.2B−₩1.7B₩642M₩684M₩729M₩776M₩826M
Free cash flow−₩4.9B₩12B₩2.1B₩2.9B₩3B₩3B₩3.1B₩3.2B
Discount factor———0.9310.8670.8070.7520.700
Present value———₩2.7B₩2.6B₩2.5B₩2.3B₩2.2B

Terminal value ₩70B, worth ₩49B today: 80% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩6,750 a share)Now 1.21×₩11,8801.76×₩20,6643.06×₩43,2156.40×
P/E on run-rate earnings (Q2 2026 × 4: ₩235 a share)Now 34.8×₩9,76841.6×₩13,88859.1×₩16,08068.4×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩6,146₩6,486₩6,902₩7,422₩8,092
6.9%₩5,600₩5,863₩6,178₩6,563₩7,044
7.4%₩5,140₩5,346₩5,589₩5,880₩6,235
7.9%₩4,747₩4,911₩5,100₩5,324₩5,591
8.4%₩4,408₩4,539₩4,688₩4,862₩5,067

Now (TTM)

Market cap
₩89B
Enterprise value
₩89B
P/E
—
P/B
1.2×
P/S
0.9×
EV/EBITDA
23.0×
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩13,000₩15,310₩23,650₩21,400₩48,550
Market cap₩142B₩167B₩258B₩233B₩530B
P/E—44.0×3,079.4×—83.1×
P/B2.1×2.3×3.8×3.9×9.2×
P/S1.6×2.1×3.1×2.9×6.7×
EV/EBITDA107.4×18.4×29.7×27.5×75.2×
Dividend yield0.0%————

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Korea Pharma—1.2×0.9×23.0×0.0%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Korea Pharma / 한국파마 / 032300 / KRX:032300

Source: KRX statistical information